Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | AHR | P35869 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | HPGD | P15428 | 5/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.42 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29948725 | 1.00 | CYP1A2 (0.46) | CYP1A2ERBB2FYNMAOAACHE | |
| SCHEMBL2381659 | 0.96 | CYP1A2 (0.46) | CYP1A2ERBB2FYNMAOAACHE | |
| SCHEMBL29556529 | 0.96 | CYP1A2 (0.46) | CYP1A2ERBB2FYNMAOAACHE | |
| SCHEMBL12947703 | 0.90 | ESR1 (0.52) | CYP1A2ERBB2FYNMAOAACHE | |
| SCHEMBL971042 | 0.89 | ESR1 (0.50) | CYP1A2ERBB2FYNMAOAACHE | |
| SCHEMBL28110227 | 0.87 | ALDH1A1 (0.43) | CYP1A2ERBB2FYNMAOAACHE | |
| SCHEMBL971061 | 0.86 | CYP1A2 (0.39) | CYP1A2ERBB2FYNMAOAACHE | |
| SCHEMBL30070892 | 0.85 | CYP1A2 (0.52) | CYP1A2ERBB2FYNMAOAACHE | |
| SCHEMBL21370813 | 0.85 | ALDH1A1 (0.56) | CYP1A2ERBB2FYNMAOAACHE | |
| SCHEMBL28344521 | 0.81 | CYP1A2 (0.43) | CYP1A2ERBB2FYNMAOAACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190091673-A1 | DISSOCIABLE NANOPARTICLES WITH INTER ALIA TRANSITION-METAL COMPLEX CATALYSTS | OXFORD FINANCE LLC | 2019-03-28 | — | — | US | claimed |
| EP-3172569-A1 | ASSAY METHODS INVOLVING DISSOCIABLE NANOPARTICLES | Selux Diagnostics Inc. (US) | 2017-05-31 | — | — | EP | claimed |
| US-20170122954-A1 | PROFILING REACTIVE OXYGEN, NITROGEN AND HALOGEN SPECIES | ENZO LIFE SCIENCES, INC., C/O ENZO BIOCHEM, INC. (US) | 2017-05-04 | — | — | US | claimed |
| WO-2017015145-A2 | DISSOCIABLE TRANSITION-METAL NANOPARTICLES | SeLux Diagnostics, Inc. (US) | 2017-01-26 | — | — | WO | claimed |
| WO-2016015027-A1 | ASSAY METHODS INVOLVING DISSOCIABLE NANOPARTICLES | SeLux Diagnostics, Inc. (US) | 2016-01-28 | — | — | WO | claimed |
| US-20150192564-A1 | PROFILING REACTIVE OXYGEN, NITROGEN AND HALOGEN SPECIES | ENZO LIFE SCIENCES, INC., C/O ENZO BIOCHEM, INC. (US) | 2015-07-09 | — | — | US | claimed |
| EP-2335052-A1 | PROFILING REACTIVE OXYGEN, NITROGEN AND HALOGEN SPECIES | Enzo Life Sciences, Inc. (US) | 2011-06-22 | — | — | EP | claimed |
| WO-2010036922-A1 | PROFILING REACTIVE OXYGEN, NITROGEN AND HALOGEN SPECIES | ENZO LIFE SCIENCES, INC. (US) | 2010-04-01 | — | — | WO | claimed |
| US-20100081159-A1 | Profiling reactive oxygen, nitrogen and halogen species | ENZO LIFE SCIENCES, INC. C/O ENZO BIOCHEM, INC. | 2010-04-01 | — | — | US | claimed |
| US-20100019169-A1 | REMOTE LASER INTERROGATION OF THREAT CLOUDS AND SURFACES | MICHIGAN MOLECULAR INSTITUTE (US) | 2010-01-28 | — | — | US | claimed |
| WO-2008118254-A2 | REMOTE LASER INTERROGATION OF THREAT CLOUDS AND SURFACES | MICHIGAN MOLECULAR INSTITUTE (US) | 2008-10-02 | — | — | WO | claimed |
| US-20070087446-A1 | Aromatic phosphonium salts and their use as labeling reagents in mass spectrometry analysis | WATERS INVESTMENTS LIMITED (US) | 2007-04-19 | — | — | US | claimed |
| JP-2006523845-A | — | — | 2006-10-19 | — | — | JP | claimed |
| US-20040259187-A1 | Methods to measure lipid antioxidant activity | ALDINI GIANCARLO (IT) | 2004-12-23 | — | — | US | claimed |
| WO-2004092707-A2 | AROMATIC PHOSPHONIUM SALTS AND THEIR USE AS LABELING REAGENTS MASS SPECTROMETRY ANALYSIS | WATERS INVESTMENTS LIMITED (US) | 2004-10-28 | — | — | WO | claimed |
| US-20020182736-A1 | Methods to measure lipid antioxidant activity | TRUSTEES OF TUFTS COLLEGE | 2002-12-05 | — | — | US | claimed |
| WO-2002082093-A2 | METHODS TO MEASURE LIPID ANTIOXIDANT ACTIVITY | TUFTS UNIVERSITY (US) | 2002-10-17 | — | — | WO | claimed |
| US-20260041711-A1 | GOLD NANOCLUSTER IN THE TREATMENT OF FRIEDREICH'S ATAXIA | NOVYSTEM S P A (IT) | 2026-02-12 | — | — | US | disclosed |
| US-5061633-A | FLUOROASSAY | TOSOH CORPORATION (JP) | 1991-10-29 | — | — | US | disclosed |
| US-4947000-A | ANALYSIS FOR LIPID PEROXIDE BY FLUORESCING UPON REACTING | TOSOH CORPORATION (JP) | 1990-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260041711-A1 | GOLD NANOCLUSTER IN THE TREATMENT OF FRIEDREICH'S ATAXIA | RTN4, QSOX1, ATXN10 | CYP1A2 4137/4885ERBB2 3571/4885FYN 3579/4885 |
| US-20100019169-A1 | REMOTE LASER INTERROGATION OF THREAT CLOUDS AND SURFACES | SELL, LGALS2, LGALS4 | CYP1A2 4329/4885ERBB2 2231/4885FYN 1435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.